metformin has been researched along with Leanness in 11 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Polycystic ovary syndrome (PCOS) is common in obese women with insulin resistant type 2 diabetes for which metformin treatment is getting established in addition to clomiphene." | 7.83 | A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin. ( Hirose, T; Kitamura, M; Kumashiro, N; Rikitake, T; Saegusa, M; Shigiyama, F; Uchino, H; Usui, S, 2016) |
| "The effect of 6 months of metformin treatment was prospectively assessed in 188 PCOS patients, divided into three groups according to body mass index (BMI; lean: BMI<25 kg/m2, overweight: BMI 25-29 kg/m2, and obese: BMI30 kg/m2)." | 7.74 | Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. ( Benson, S; Dietz, T; Elsenbruch, S; Hahn, S; Janssen, OE; Kimmig, R; Lahner, H; Mann, K; Moeller, LC; Schmidt, M; Tan, S, 2007) |
| "This study was carried out to compare ovulation and pregnancy rates in response to metformin therapy in lean and obese women with polycystic ovary syndrome (PCOS)." | 7.73 | Metformin monotherapy in lean women with polycystic ovary syndrome. ( Abdel-Wareth, LO; Al Haija, SA; Alvares, M; Haq, A; Jayasundaram, R; Kumari, AS, 2005) |
| "Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well." | 7.73 | The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M, 2005) |
| "Polycystic ovary syndrome (PCOS) is common in obese women with insulin resistant type 2 diabetes for which metformin treatment is getting established in addition to clomiphene." | 3.83 | A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin. ( Hirose, T; Kitamura, M; Kumashiro, N; Rikitake, T; Saegusa, M; Shigiyama, F; Uchino, H; Usui, S, 2016) |
| " Metformin treatment improved the insulin sensitivity, and normalized the in vitro bladder hypercontractility and cystometric dysfunction in obese mice." | 3.78 | Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice. ( Anhê, GF; Antunes, E; Calixto, MC; De Nucci, G; Grant, AD; Leiria, LO; Lintomen, L; Mónica, FZ; Sollon, C; Zanesco, A, 2012) |
| "The effect of 6 months of metformin treatment was prospectively assessed in 188 PCOS patients, divided into three groups according to body mass index (BMI; lean: BMI<25 kg/m2, overweight: BMI 25-29 kg/m2, and obese: BMI30 kg/m2)." | 3.74 | Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. ( Benson, S; Dietz, T; Elsenbruch, S; Hahn, S; Janssen, OE; Kimmig, R; Lahner, H; Mann, K; Moeller, LC; Schmidt, M; Tan, S, 2007) |
| "This study was carried out to compare ovulation and pregnancy rates in response to metformin therapy in lean and obese women with polycystic ovary syndrome (PCOS)." | 3.73 | Metformin monotherapy in lean women with polycystic ovary syndrome. ( Abdel-Wareth, LO; Al Haija, SA; Alvares, M; Haq, A; Jayasundaram, R; Kumari, AS, 2005) |
| "Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well." | 3.73 | The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M, 2005) |
| "Type 2 diabetes is characterized by insulin resistance, hyperinsulinemia and hepatic overproduction of glucose and lipids." | 1.48 | Coordinated regulation of hepatic FoxO1, PGC-1α and SREBP-1c facilitates insulin action and resistance. ( Cleland, C; Farese, RV; Foufelle, F; Lee, MC; Sajan, J; Sajan, MP, 2018) |
| "Obesity-driven Type 2 diabetes (T2D) is a systemic inflammatory condition associated with cardiovascular disease." | 1.48 | Inflammatory signatures distinguish metabolic health in African American women with obesity. ( Andrieu, G; Bertrand, KA; Denis, GV; Medina, ND; Palmer, JR; Sebastiani, P; Slama, J; Strissel, KJ; Tran, AH, 2018) |
| "Insulin resistance was assessed by 3-h oral glucose tolerance test (OGTT)." | 1.46 | Metabolic and androgen profile in underweight women with polycystic ovary syndrome. ( Anastasiou, OE; Canbay, A; Fuhrer, D; Reger-Tan, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anastasiou, OE | 1 |
| Canbay, A | 1 |
| Fuhrer, D | 1 |
| Reger-Tan, S | 1 |
| Sajan, MP | 1 |
| Lee, MC | 1 |
| Foufelle, F | 1 |
| Sajan, J | 1 |
| Cleland, C | 1 |
| Farese, RV | 1 |
| Denis, GV | 1 |
| Sebastiani, P | 1 |
| Bertrand, KA | 1 |
| Strissel, KJ | 1 |
| Tran, AH | 1 |
| Slama, J | 1 |
| Medina, ND | 1 |
| Andrieu, G | 1 |
| Palmer, JR | 1 |
| Shigiyama, F | 1 |
| Kumashiro, N | 1 |
| Rikitake, T | 1 |
| Usui, S | 1 |
| Saegusa, M | 1 |
| Kitamura, M | 1 |
| Uchino, H | 1 |
| Hirose, T | 1 |
| Bedford, DC | 1 |
| Kasper, LH | 1 |
| Wang, R | 1 |
| Chang, Y | 1 |
| Green, DR | 1 |
| Brindle, PK | 1 |
| Cinar, N | 1 |
| Harmanci, A | 1 |
| Bayraktar, M | 1 |
| Yildiz, BO | 1 |
| Leiria, LO | 1 |
| Sollon, C | 1 |
| Calixto, MC | 1 |
| Lintomen, L | 1 |
| Mónica, FZ | 1 |
| Anhê, GF | 1 |
| De Nucci, G | 1 |
| Zanesco, A | 1 |
| Grant, AD | 1 |
| Antunes, E | 1 |
| Kumari, AS | 1 |
| Haq, A | 1 |
| Jayasundaram, R | 1 |
| Abdel-Wareth, LO | 1 |
| Al Haija, SA | 1 |
| Alvares, M | 1 |
| Yilmaz, M | 1 |
| Biri, A | 1 |
| Karakoç, A | 1 |
| Törüner, F | 1 |
| Bingöl, B | 1 |
| Cakir, N | 1 |
| Tiras, B | 1 |
| Ayvaz, G | 1 |
| Arslan, M | 1 |
| Tan, S | 1 |
| Hahn, S | 1 |
| Benson, S | 1 |
| Dietz, T | 1 |
| Lahner, H | 1 |
| Moeller, LC | 1 |
| Schmidt, M | 1 |
| Elsenbruch, S | 1 |
| Kimmig, R | 1 |
| Mann, K | 1 |
| Janssen, OE | 1 |
| Al-Ozairi, E | 1 |
| Quinton, R | 1 |
| Advani, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau[NCT05591339] | Phase 4 | 200 participants (Anticipated) | Interventional | 2023-03-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 other studies available for metformin and Leanness
| Article | Year |
|---|---|
Metabolic and androgen profile in underweight women with polycystic ovary syndrome.
Topics: Adult; Androgens; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Hypoglycemic Ag | 2017 |
Coordinated regulation of hepatic FoxO1, PGC-1α and SREBP-1c facilitates insulin action and resistance.
Topics: Adult; Aged; Animals; Cyclopentanes; Diabetes Mellitus, Type 2; Diet, High-Fat; Female; Forkhead Box | 2018 |
Inflammatory signatures distinguish metabolic health in African American women with obesity.
Topics: Biomarkers; Black or African American; Chemokines; Cytokines; Diabetes Mellitus, Type 2; Female; Gly | 2018 |
A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin.
Topics: Adult; Diabetes Mellitus, Type 1; Disease Progression; Female; Humans; Hypoglycemic Agents; Metformi | 2016 |
Disrupting the CH1 domain structure in the acetyltransferases CBP and p300 results in lean mice with increased metabolic control.
Topics: Animals; Blood Glucose; Cells, Cultured; CREB-Binding Protein; Diet; Energy Metabolism; Female; Gluc | 2011 |
Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome.
Topics: Androstenes; Ethinyl Estradiol; Female; Humans; Male; Metformin; Middle Aged; Polycystic Ovary Syndr | 2013 |
Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice.
Topics: Adiposity; Amlodipine; Animals; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Cal | 2012 |
Metformin monotherapy in lean women with polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Metformin; Obesity; Polycystic Ovary Syndrome; Thinness | 2005 |
The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
Topics: Adult; Androgens; Blood Glucose; Body Mass Index; Fasting; Female; Follicle Stimulating Hormone; Glu | 2005 |
Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance.
Topics: Body Weight; Female; Humans; Insulin Resistance; Metformin; Obesity; Overweight; Polycystic Ovary Sy | 2007 |
Therapeutic response to metformin in an underweight patient with polycystic ovarian syndrome.
Topics: Adult; Female; Fetal Proteins; Humans; Hypoglycemic Agents; Insulin; Menstrual Cycle; Metformin; Pol | 2008 |